Literature DB >> 21250786

Pharmacokinetic interaction between ϵ-acetamidocaproic acid (AACA) and cimetidine in indomethacin-induced acute gastric ulcer and control rats: inhibition of active renal secretion of AACA by cimetidine.

Y H Choi1, U Lee, J H Suh, Y G Kim, M Lee, E Oh, M G Lee.   

Abstract

After both the intravenous and oral administration of zinc acexamate [ZAC; ion-pairing between zinc and ϵ-acetamidocaproic acid (AACA)] and cimetidine together, the areas under the curve (AUCs) of AACA were significantly greater [by 28.2 and 98.9% after the intravenous and oral administration, respectively, for control rats and 13.5 and 16.9% for indomethacin-induced acute gastric ulcer (IAGU) rats, respectively] than those of ZAC alone due to the significantly slower renal clearance (CL(R)). The significantly greater AUCs of AACA after both the intravenous and oral administration of ZAC and cimetidine together in control and IAGU rats could have been due to the inhibition of active renal tubular secretion of AACA by cimetidine. After the intravenous and oral administration of both drugs together, the AUCs of cimetidine in control and IAGU rats were not different compared with those with cimetidine alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21250786     DOI: 10.3109/00498254.2010.549250

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of ε-Acetamidocaproic Acid in Rat Plasma.

Authors:  Tae Hyun Kim; Yong Seok Choi; Young Hee Choi; Yoon Gyoon Kim
Journal:  Toxicol Res       Date:  2013-09

2.  Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.

Authors:  Im-Sook Song; Tae Yeon Kong; Hyeon-Uk Jeong; Eun Nam Kim; Soon-Sang Kwon; Hee Eun Kang; Sang-Zin Choi; Miwon Son; Hye Suk Lee
Journal:  BMC Complement Altern Med       Date:  2014-07-17       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.